Clinical Trial Update: A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety and efficacy study of intranasal esketamine for treatment-resistant depression has completed, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Treatment-resistant Depression

Drugs mentioned

• Spravato (esketamine) (esketamine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Treatment-resistant Depression | Phase 3 | Status: COMPLETED | Results posted: 2019-04-29